Clinical evaluation of mezlocillin.
The safety and efficacy of intravenous mezlocillin were determined in 25 patients with aerobic, anaerobic, and mixed infections. Included were pleuropulmonary, urinary tract, skin, and soft-tissue infections, osteomyelitis, and abdominal and breast abscess. Nineteen patients (76%) were cured without recurrence as determined by clinical and bacteriological parameters. In three, the infection recurred (12%); two patients failed (8%), and in one, it was indeterminate (4%). No serious adverse effects were noted except for severe thrombophlebitis in three (12%) patients. Our preliminary data suggest that mezlocillin is a safe (except for thrombophlebitis) and effective antibiotic in the treatment of aerobic anaerobic, and mixed infections.
D000038:Abscess / Q000188:drug therapy; D000332:Aerobiosis; D000693:Anaerobiosis; D001424:Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D010019:Osteomyelitis / Q000188:drug therapy; D010406:Penicillins / Q000009:adverse effects / Q000627:therapeutic use*; D010998:Pleurisy / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D010406:Penicillins